Moderna Announces Clinical and Program Updates at 4th Vaccines Day

Go back to Moderna Announces Clinical and Program Updates at 4th Vaccines Day

BofA expresses concerns about Moderna (MRNA) guidance, which 'may be a high bar'

April 12, 2023 11:24 AM EDT

BofA was left with more questions than answers following Moderna's (NASDAQ: MRNA) Vaccines Day, analyst Geoff Meacham told investors in a note Wednesday.

The analyst, who has a Neutral rating and $200 price target on Moderna, said the firm "wouldn't be surprised if shares... More

Moderna (MRNA) Declines Following Clinical and Program Updates, Down 7%

April 11, 2023 7:08 AM EDT

Moderna (NASDAQ: MRNA) Declines Following Clinical and Program Updates, Down 7%

Company's first influenza candidate, mRNA-1010, did not accrue sufficient cases at the interim efficacy analysis to declare early success in the Phase 3 Northern Hemisphere efficacy trial and the independent DSMB recommended continuation of efficacy follow-up

... More